Verified Beauty Data

Ingredient dossier Nº 012 / The verified record

Tranexamic Acid

TRANEXAMIC ACID · CosIng 68411 · also TXA, trans-AMCHA, trans-4-aminomethylcyclohexanecarboxylic acid

Effective concentration, the pH it needs, how the derivatives compare, stability in the bottle, and the open questions — every scientific claim on this page links to its source.

Editorial verdict / Social intelligence

Qualified yes Ingredient dossier

The derm-favorite for stubborn melasma that vitamin C can't crack — genuinely works, but it's a marathon not a sprint, and oral beats topical for severe cases. 1

Beauty benefit
The most targeted topical ingredient for melasma and inflammation-driven hyperpigmentation — works upstream of pigment formation by interrupting the UV/inflammation signals that tell melanocytes to overproduce, and separately shrinks the vascular component of melasma. More specific to stubborn, hormonally driven pigmentation than vitamin C or niacinamide, and usable long-term without the Rx-only constraints of hydroquinone.
Does it work
Yes — qualified. Topical tranexamic acid at 2-5% has strong clinical evidence for melasma: a 2017 meta-analysis of 11 studies (667 participants) showed measurable MASI reduction, and a split-face RCT found 3% TXA equivalent to 4% hydroquinone. Oral TXA (prescription, dermatologist-managed) is significantly more effective for severe cases. The honest caveats: results are slow (visible improvement at 4-8 weeks; meaningful results at 3 months), topical penetration is inherently limited by the molecule's hydrophilicity, and melasma almost always recurs after stopping any treatment. Vitamin C often plateaus on deep melasma precisely where TXA delivers — but TXA is no magic eraser and sunscreen compliance is non-negotiable. See the science below →

Consensus strength

Strong

Strong dermatologist and clinical consensus that tranexamic acid is the leading non-hydroquinone topical for melasma, validated by multiple RCTs, a 2017 meta-analysis (PMID:28374042), a 2024 network meta-analysis across 32 studies/2,376 patients, and a 2025 systematic review. Marie Claire's beauty editors call it 'every beauty editor's holy grail brightening ingredient'; Dr. Mona Gohara (Marie Claire) and other board-certified dermatologists consistently recommend it for melasma and PIH. Honest dissent from Dr. Davin Lim (Melasma Clinic): topical serums are 'trending and over-marketed' compared to systemic/laser protocols, and 'serum marketing far exceeds systemic therapy.' DermNet NZ acknowledges the mechanism is 'not fully understood' and recurrence on stopping is consistent. No dissent on topical safety; minor dissent on topical-alone efficacy for severe melasma.

01 / What it does

What it does

Tranexamic acid is a synthetic lysine analog originally developed as an oral antifibrinolytic drug to control bleeding. In skin, it inhibits the plasminogen-to-plasmin conversion pathway in keratinocytes, which reduces UV- and inflammation-induced release of arachidonic acid and downstream prostaglandin production — signals that normally stimulate adjacent melanocytes to increase tyrosinase activity and melanin synthesis. Separately, tranexamic acid suppresses vascular endothelial growth factor receptor (VEGFR) signaling, reducing the angiogenesis and erythema component of melasma. This dual anti-melanogenic and anti-angiogenic mechanism distinguishes it from tyrosinase-inhibitors such as kojic acid or ascorbic acid, which act primarily at a downstream enzymatic step. It is the most studied oral and topical depigmenting agent after hydroquinone, with the strongest evidence in melasma and post-inflammatory hyperpigmentation.

02 / Effective concentration

What percentage actually works

Effective range

2-5%

Topical tranexamic acid is used at 2-5% in cosmetic and clinical formulations; 3% is the most common clinical benchmark. The original mechanism study used 2-3% in guinea pig models. Expert consensus supports topical TXA at 2%, particularly with delivery-optimized systems. Oral dosing (250-500 mg/day, off-label) is a separate route used in clinical practice for refractory melasma.

The original Maeda & Naganuma (1998) guinea pig study demonstrated efficacy at 2-3% topical concentration. Clinical trials comparing 3% topical tranexamic acid to 4% hydroquinone found equivalent reductions in mMASI scores at 4 and 8 weeks in a split-face RCT (n=20). Expert consensus has focused on 2% topical TXA with advanced delivery technology as a practical formulation target. A 2025 RCT tested conventional TXA at 5% combined with niacinamide 4% and found equivalent efficacy to 4% hydroquinone in melasma with fewer adverse effects. Concentrations below 2% lack controlled clinical efficacy data; concentrations above 5% in topical cosmetics have not demonstrated proportionally superior clinical outcomes in published literature. For oral use in clinical settings, 250 mg twice daily or 500 mg once daily are the documented regimens — these are pharmaceutical, not cosmetic, doses.

  • Study Post-exposure application of 2% and 3% topical trans-AMCHA solutions prevented or inhibited UV-induced pigmentation in guinea pig skin; the 3% concentration showed more complete inhibition. 1
  • Study In a double-blind split-face RCT (n=20, 8 weeks), 3% tranexamic acid cream produced a significant decline in mMASI score at weeks 4 and 8 comparable to 4% hydroquinone, with no meaningful differences in patient satisfaction. 15
  • Study Expert consensus recommends topical TXA 2% with patented delivery technology for melasma management in patients who have failed or are intolerant of hydroquinone. 11
  • Study In a 99-patient RCT, conventional TXA 5% combined with niacinamide 4% was as effective as hydroquinone 4% cream in reducing melasma melanin levels and clinical severity scores, with fewer adverse effects including reduced relapse rate. 17
  • Study A systematic review and meta-analysis of 11 studies (667 participants) found that tranexamic acid monotherapy produced a pooled MASI decrease of 1.60 points (95% CI 1.20-2.00; p<0.001); as an adjuvant it added an additional reduction of 0.94 points (p=0.03). 2

One honest caveat The landmark mechanism study (Maeda & Naganuma 1998, PMID:10093913) used a guinea pig model; the arachidonic acid/prostaglandin pathway for melanogenesis inhibition has not been replicated in a controlled human keratinocyte or in vivo human skin study at the molecular level.

03 / pH requirement

The pH it needs

Target pH

Approximately pH 4-7; formulation-tolerant

Tranexamic acid is water-soluble and chemically stable across a broad pH range, unlike L-ascorbic acid which requires pH below 3.5 for percutaneous absorption. Its zwitterionic nature (amphoteric amino acid structure) means it does not require an acidic vehicle for formulation; most topical products are formulated at physiological pH 4-7 without compromising stability. Aqueous solutions of tranexamic acid have been shown to retain above 97% concentration after 31 days at both 23°C and 5°C. This broad formulation tolerance makes tranexamic acid suitable for gentle, skin-compatible vehicles, including those designed for sensitive skin and post-procedure use — an advantage over L-ascorbic acid and azelaic acid formulations. Delivery enhancement (liposomes, niosomes, microneedling) has been studied to improve percutaneous penetration, which is limited by the molecule's hydrophilicity.

  • Study Tranexamic acid mouth rinse solutions retained above 97.2% of initial concentration after 31 days storage at 23°C or 5°C, demonstrating excellent aqueous chemical stability across ambient and refrigerated temperatures. 21
  • Study Topical tranexamic acid liposome formulations were developed at 5-10% concentration in deionized water; encapsulation efficiency was 13.2-15.6%, and charged liposomes demonstrated better physical stability than neutral liposomes, enabling topical delivery without requiring low-pH vehicles. 22

04 / Derivative ladder

How the derivatives compare

Every derivative trades a measure of proven activity for stability or gentleness. Skin conversion is the question that matters — a more stable molecule only helps if your skin can turn it back into the active form.

  1. Cetyl Tranexamate Mesylate

    CETYL TRANEXAMATE HCL

    A lipophilic ester derivative of tranexamic acid formed by esterification of the carboxyl group with cetyl alcohol. The longer fatty chain increases skin permeability compared to parent tranexamic acid. A clinical study using 2% cetyl tranexamate mesylate in a facial serum over 8 weeks demonstrated -16.9% reduction in melanin index and -34.3% reduction in erythema index from baseline, with 79.3% of participants reporting improved skin tone within 2 weeks and no documented adverse reactions. The ester must be hydrolyzed to release free tranexamic acid in skin; conversion rate in vivo has not been formally quantified.

    • Study Cetyl tranexamate mesylate 2% applied twice daily for 8 weeks significantly reduced melanin index (-16.9%) and erythema index (-34.3%) from baseline, with no adverse reactions documented in safety testing. 20

  2. Tranexamic Acid Alkyl Esters (Butyl, Octyl, Decyl, Dodecyl)

    Various — not standardized in INCI

    A series of biodegradable ester derivatives of tranexamic acid studied primarily as transdermal permeation enhancers. The dodecyl ester at 1% demonstrated an enhancement ratio of 4.3 versus vehicle in porcine skin; the decyl ester in isopropyl myristate achieved 4.9. These compounds decompose in slightly acidic conditions and are hydrolyzed by skin esterases, potentially releasing parent tranexamic acid. Current evidence is from permeation studies in porcine skin; they are not established cosmetic actives with independent brightening clinical trial data.

    • Study Tranexamic acid dodecyl ester at 1% in aqueous vehicle achieved an enhancement ratio of 4.3 ± 0.9 compared to the commercial enhancer Azone; biodegradability via esterase hydrolysis was confirmed in porcine tissue. 23

05 / Stability & storage

Stability in the bottle

Tranexamic acid is notably more stable than L-ascorbic acid in aqueous cosmetic formulations. As a non-reducing amino acid analog, it is not susceptible to oxidative degradation by oxygen or metal ions. Aqueous solutions maintain above 97% purity over 31 days at room temperature. It does not discolor in solution and does not produce degradation products that would compromise formulation aesthetics. The primary formulation challenge is penetration, not stability: tranexamic acid is hydrophilic and polar, limiting passive diffusion through the lipid-rich stratum corneum. This has driven research into delivery vehicles including liposomes (PMID:11879740), niosomes (PMID:41315336), and physical delivery methods (microneedling) to improve bioavailability. Tranexamic acid esters are more lipophilic and penetrate the stratum corneum more readily but require hydrolysis to parent acid in skin; their stability as formulated intermediates varies by ester chain length.

In practice Buy it in an opaque, airless, or amber container, store it cool and out of the light, and treat a colour shift toward orange or brown as the signal to replace it — the molecule is telling you it has already oxidised.

06 / How to use it

How to actually use Tranexamic Acid

When
AM or PM — After cleansing, before moisturizer.
Pairs well with
niacinamide, vitamin C, alpha-arbutin.
Apply apart from
Nothing major — it layers comfortably with most actives.
What to look for
2–5% topical.
Heads-up
Gentle and layers well; a strong pick for melasma and red post-acne marks (PIE).

Practical guidance for routine placement — not a substitute for a dermatologist’s advice for your skin.

07 / The database

Every Tranexamic Acid product, cheapest active-gram first

Ranked by $ per gram of active — what the working ingredient actually costs you, not the sticker price. Rows we have reviewed in full link through; the rest are data points from the same crawl.

Buy Naturium on Amazon $19.99 Top-ranked pick · affiliate link

# Product % Price $ / g of active
1 FARMACY Brighten Up 3% TXA Dark Spot Toner - 4.0 oz Ulta 3% $34.00 $9.58
2 Naturium Tranexamic Topical Acid 5% Reviewed in full 5% $19.99 $13.52

Showing the 2 lowest-cost of 2 measured .

Contains it, but doesn't disclose a percentage: Good MoleculesBrightening & Dark Spots Bar ; Hero CosmeticsMighty Patch Micropoint for Dark Spot Patches ; PanOxylPM Blemish Aftercare Brightening Patches ; STARFACEHydro-Star Recovery Patches ; BubbleDay Dream Vitamin C + Niacinamide Tone & Texture Serum ; SOME BY MIRetinol Intense Anti Aging Trial Kit — and 14 more.

08 / Safety

Is it safe?

No standalone CIR assessment exists

No finalized CIR Expert Panel report for Tranexamic Acid as a cosmetic ingredient has been located in the public CIR database as of the last_reviewed date. The ingredient does not appear on the CIR Approved or Final Report list for topical cosmetic use. Regulatory status: Tranexamic acid is an approved pharmaceutical drug (oral and intravenous) in many jurisdictions for its antifibrinolytic indications; its cosmetic use is as an active depigmenting ingredient, which is not subject to the same pharmaceutical pre-approval pathway in most markets. EU CosIng lists tranexamic acid (ref. 68411) as a cosmetic ingredient with a skin-conditioning function. It is not included in Annex II (prohibited) or Annex III (restricted) of the EU Cosmetics Regulation.

TOPICAL SAFETY: Multiple clinical trials at 2-5% topical concentration report no significant adverse events; side effects are rare and generally limited to transient skin irritation. The 3% vs 4% hydroquinone split-face RCT found comparable tolerability with potential advantages over hydroquinone (no ochronosis risk, lower irritation rate). ORAL SAFETY AND THE BLOOD CLOT QUESTION: Oral tranexamic acid is a prescription pharmaceutical. At the low doses used for melasma (250-500 mg/day, versus 3-6 g/day in surgical hemostasis), a large retrospective study (n=561) reported adverse events in only 7.1% of patients, primarily transient and minor; one patient developed DVT and was subsequently diagnosed with familial protein S deficiency (PMID:27206758). A 2025 multicenter propensity-matched EHR cohort study found no significant association between low-dose oral TXA for melasma and thromboembolic events (PMID:41256337). CRITICAL REPRESENTATION: the oral anticoagulation concern stems from tranexamic acid's antifibrinolytic mechanism in the systemic circulation and is DOSE- AND ROUTE-DEPENDENT. Topical application at cosmetic concentrations results in minimal systemic absorption. The clotting risk is not equivalent for topical cosmetic use; the two routes must not be conflated in consumer communication.

  • Study In a retrospective analysis of 561 patients treated with oral TXA for melasma, adverse events occurred in 7.1%, primarily transient; one case of DVT was documented in a patient later found to have familial protein S deficiency. The authors concluded careful pre-treatment screening for personal and familial thromboembolic risk factors is required. 18
  • Study A multicenter propensity score-matched EHR cohort study found oral tranexamic acid use for melasma is not associated with thromboembolic events; oral TXA at low dermatological doses does not increase thromboembolic risk in screened populations. 19
  • Study In a split-face RCT (n=20), topical 3% TXA cream was as effective and safe as 4% hydroquinone for mixed-type melasma with no meaningful differences in tolerability or adverse events. 15
  • Study A systematic review and meta-analysis of 11 studies (667 participants) found side effects of tranexamic acid for melasma were minor, with a few cases reporting hypomenorrhoea and mild abdominal discomfort (both with oral use) and transient skin irritation (topical); no serious dermatological adverse events were reported. 2

09 / The limits of the evidence

What we don't know yet

Most of what you read about this ingredient is stated with more certainty than the evidence earns. Here is exactly where the record thins out — so you can weigh the claims above for yourself.

  1. The landmark mechanism study (Maeda & Naganuma 1998, PMID:10093913) used a guinea pig model; the arachidonic acid/prostaglandin pathway for melanogenesis inhibition has not been replicated in a controlled human keratinocyte or in vivo human skin study at the molecular level.
  2. No published head-to-head RCT directly compares topical tranexamic acid to L-ascorbic acid or kojic acid for melasma using standardized MASI scoring in a well-powered trial.
  3. The skin penetration of topical tranexamic acid is limited by its hydrophilicity; most clinical trials do not report measured drug levels in skin, so effective local concentration at the keratinocyte level is inferred, not directly quantified.
  4. Long-term (>6 months) clinical data on topical tranexamic acid for maintenance therapy of melasma are limited; recurrence rates after discontinuation are not well-characterized in the topical TXA literature.
  5. The optimal topical concentration for cosmetic use has not been established by dose-ranging trials in humans; the 2-5% range derives from mechanism studies (guinea pig), comparative RCTs, and expert consensus rather than dedicated dose-finding studies.
  6. Evidence for tranexamic acid in post-inflammatory hyperpigmentation, Riehl's melanosis, and rosacea is emerging but based on smaller or retrospective studies; it is not as robustly supported as its melasma evidence base.
  7. CIR has not issued a finalized safety assessment specifically for tranexamic acid as a cosmetic ingredient; the safety profile is inferred from pharmaceutical use data (oral/IV) and cosmetic clinical trials.
  8. The vascular/anti-angiogenic mechanism data (PMID:32308543, PMID:31074159) come from in vitro cell models; the relative contribution of anti-angiogenesis vs anti-melanogenesis to the clinical lightening effect in human melasma lesions is not quantified.

10 / What people say

What formulators and users say

What works

  • Common Targets melasma at the source — blocks the UV/inflammation signals that trigger melanocytes before pigment is ever made, a more upstream intervention than tyrosinase inhibitors like vitamin C 1412
    Tranexamic acid blocks those messages, specifically the pathways between inflammation, blood vessels, and pigment production. Tranexamic acid turns off the faucet that keeps refilling the sink. — Dr. Mona Gohara, MD Dermatologist
  • Common Equivalent to 4% hydroquinone for melasma in RCTs — without hydroquinone's irritation, ochronosis risk, or need for treatment breaks 41
    tranexamic acid is 'as effective as the prescription ingredient hydroquinone for melasma' and 'can be used safely for long periods without breaks – unlike hydroquinone' Editorial
  • Common Exceptional safety profile — well-tolerated by sensitive skin, darker skin tones, and rosacea-prone skin types that cannot use stronger actives 753
    Tranexamic acid is great for anyone dealing with hyperpigmentation, melasma, or acne scarring, especially those with sensitive skin who may not tolerate stronger ingredients — Dr. Dara Spearman, MD Dermatologist
  • Some No sun-sensitivity penalty — unlike AHA exfoliants, tranexamic acid does not increase photosensitivity, making it compatible with morning routines without heightened UV risk 1110
    isn't known to make your skin more sensitive to the sun Editorial
  • Common Stacks powerfully with other brighteners — niacinamide, vitamin C, kojic acid, and retinoids are all documented compatible pairings that address pigmentation at complementary steps 78
    It plays well with other brightening agents like niacinamide, vitamin C, kojic acid, and licorice root, and can even be layered with retinoids if your skin can tolerate it — Dr. Dara Spearman, MD Dermatologist
  • Some Oral tranexamic acid (prescription) achieves 49-95% MASI improvement and is dermatologists' preferred route for severe or refractory melasma 122
    250–500 mg twice daily showed 49%–95% improvement in MASI scores; 94.6% showed improvement within 1–2 months Study

What to know

  • Common Results are slow — meaningful improvement takes 6-12 weeks of consistent use; many users expect faster results and abandon the ingredient prematurely 126
    Pigment treatments are marathons, not sprints. — Dr. Mona Gohara, MD Dermatologist
  • Some Topical-only approach has real limitations — limited skin penetration due to the molecule's hydrophilicity means serum efficacy is substantially weaker than oral or intradermal TXA for moderate-to-severe melasma 212
    This works in 20 to 80% of melasma. The lower figure quoted is for serums, the higher figure is when it is used systemically with lasers, pigment inhibitors and chemical peels. Serum marketing far exceeds systemic therapy. — Dr. Davin Lim derm-review
  • Common Melasma recurs after stopping — high relapse rates mean TXA is a management tool, not a cure; patients need maintenance strategies and ongoing sun protection 31
    On stopping treatment with tranexamic acid, the disease may recur derm-review
  • Some Topical side effects do occur — dryness, scaling, flaking, and occasional irritation; rare allergic reactions reported requiring discontinuation 512
    Redness, mild itching and skin dryness can sometimes occur in the areas you apply tranexamic acid Editorial
  • Some Not an exfoliant — the 'acid' name misleads consumers who expect the keratolytic action of a glycolic or salicylic acid; it does nothing for texture, congestion, or cell turnover 910
    Tranexamic acid is not an exfoliant. Despite its name, it is not an exfoliating acid like AHAs and BHAs. Editorial

What you'd only know from the reviews

  • The topical vs. oral gap is enormous and rarely communicated in serum marketing. Oral TXA (a prescription, 250-500 mg/day) achieves 49-95% MASI improvement; topical serums achieve closer to 20-40% at the low end. A dermatologist who uses both will almost always reach for oral TXA for moderate-to-severe melasma. If topical TXA hasn't moved your melasma after 12 weeks, the issue may be delivery route, not the ingredient. 212

  • Tranexamic acid addresses two mechanisms other brighteners miss entirely: angiogenesis and erythema. The redness and blood vessel dilation in melasma lesions are not targeted by vitamin C, niacinamide, or kojic acid — only TXA directly suppresses VEGF receptor signaling to shrink the vascular component. This is why melasma that looks 'pink-brown' may respond better to TXA than to purely melanin-focused actives. 12

  • Tranexamic acid is not licensed for dermatological use in most countries — it is a prescription pharmaceutical being used off-label. The oral form requires physician screening for thromboembolic risk factors; healthy individuals at low doses show no elevated clotting risk in studies, but patients with personal or family history of DVT, PE, or clotting disorders need medical evaluation before oral use. 312

  • Sunscreen is not optional — it is co-therapy. Tranexamic acid interrupts UV-triggered pigmentation signals, but if UV continues stimulating the pathway daily, TXA is running to stay in place. Studies show results diminish quickly without consistent broad-spectrum SPF 30+. For melasma patients, sunscreen is mechanistically part of the treatment, not a nice-to-have add-on. 14

  • Tranexamic acid works on rosacea in ways no other brightener does — its anti-angiogenic mechanism makes it uniquely relevant for rosacea-driven erythema and the post-inflammatory pigmentation that follows rosacea flares. Emerging 2024 data (oral TXA) shows improved skin barrier function and reduced flushing, which is completely outside the scope of any melanin-targeting ingredient. 121

  1. 1 Dermatologist Why Tranexamic Acid Is Every Beauty Editor's Holy Grail Brightening Ingredient — Marie Claire (Dr. Mona Gohara, MD) 2024
  2. 2 derm-review Effective Tranexamic Acid For Melasma: Dermatologist Review — Melasma Clinic (Dr. Davin Lim) 2024
  3. 3 derm-review Tranexamic acid — DermNet NZ 2024
  4. 4 Editorial Why Everyone's Talking About Tranexamic Acid for Hyperpigmentation — Dermatica SkinLab 2024
  5. 5 Editorial Tranexamic Acid Side Effects In Skincare — Dermatica SkinLab 2024
  6. 6 Editorial Tranexamic Acid for Skin: Benefits, Safety, How to Use — Healthline (Dr. Anna Guanche, Dr. Mary Stevenson, Dr. Hadley King) 2024
  7. 7 Dermatologist Move Over Vitamin C, Tranexamic Acid is Skin Care's Best-Kept Secret — AOL Health (Dr. Dara Spearman, MD) 2024
  8. 8 Editorial Can You Use Tranexamic Acid With Vitamin C? — Cosmetify 2024
  9. 9 Editorial What Does Tranexamic Acid Do for Skin? — Truly Beauty 2024
  10. 10 Editorial Is Tranexamic Acid an Exfoliant? — Perfect Image 2024
  11. 11 Editorial Everything you need to know about Tranexamic Acid — Medik8 2024
  12. 12 Study Tranexamic Acid for Hyperpigmentation Disorders: A Literature Review on Efficacy and Safety in Melasma and PIH — PMC 2025
  13. 13 Study Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review — PubMed PMID:28374042 2017

11 / Questions

Frequently asked

What does tranexamic acid do for skin?
Tranexamic acid reduces unwanted pigmentation through two distinct mechanisms. First, it inhibits the plasminogen-to-plasmin conversion in keratinocytes; this reduces UV- and inflammation-triggered arachidonic acid release and downstream prostaglandin signaling, which would otherwise stimulate melanocytes to increase melanin production. Second, it suppresses VEGF receptor signaling, reducing the angiogenesis and erythema components of conditions like melasma — accounting for its effect on the redness and vascular pattern that characterise that condition, not just the brown pigmentation. This dual action distinguishes tranexamic acid from straightforward tyrosinase inhibitors like kojic acid or vitamin C. 156
Is tranexamic acid good for melasma and dark spots?
Yes — tranexamic acid has the strongest evidence base of any non-hydroquinone topical agent for melasma. A 2017 meta-analysis of 11 studies (667 participants) found tranexamic acid monotherapy reduced the Melasma Area and Severity Index (MASI) by 1.60 points (p<0.001); a split-face RCT found 3% topical TXA equivalent in efficacy to 4% hydroquinone over 8 weeks. It also reduces post-inflammatory hyperpigmentation and has been investigated for rosacea-associated erythema, Riehl's melanosis, and post-acne erythema. Evidence for PIH specifically is emerging (review: PMID:39350932) but the controlled trial base is smaller than for melasma. 21516
Tranexamic acid vs vitamin C vs niacinamide for brightening — which is best?
They act at different steps and are not interchangeable. Tranexamic acid acts upstream — on the keratinocyte signaling that triggers melanocytes — and also targets angiogenesis; this makes it the most targeted option for inflammatory or UV-triggered pigmentation like melasma. Vitamin C (L-ascorbic acid) inhibits tyrosinase directly by reducing the copper active site, and additionally provides antioxidant and photoprotective activity, but requires pH below 3.5 for delivery. Niacinamide interrupts melanosome transfer from melanocytes to keratinocytes, a distinct downstream step, and is gentle and well-tolerated at 4-5%. Clinical trial data favor tranexamic acid specifically for melasma over isolated vitamin C or niacinamide; combinations of TXA + niacinamide have been tested and shown equivalent results to hydroquinone with fewer side effects. Evidence-based formulations often combine all three for complementary action on the pigmentation cascade. 1729
What percentage of topical tranexamic acid is effective?
Controlled clinical evidence supports 2-5% topical tranexamic acid. The original mechanism study by Maeda & Naganuma (1998) used 2-3% in guinea pig models. A split-face RCT demonstrated 3% effective vs 4% hydroquinone. Expert consensus from a 2023 multi-country panel recommended 2% with optimized delivery technology. A 2025 RCT found 5% (combined with niacinamide 4%) equivalent to 4% hydroquinone. The 3% mark is the most replicated concentration in published clinical trials. There is no published evidence that concentrations above 5% provide additional clinical benefit in topical cosmetic application. 1151117
Is topical tranexamic acid safe — will it cause blood clots?
The blood clot concern comes from tranexamic acid's pharmaceutical oral form, used at 3-6 g/day in surgical hemostasis — doses orders of magnitude above cosmetic topical use. For melasma, even the oral dermatological dose (250-500 mg/day) was not associated with thromboembolic events in a 2025 multicenter propensity-matched cohort study (PMID:41256337); a single DVT case in a large retrospective series (PMID:27206758) occurred in a patient with underlying familial protein S deficiency. For topical cosmetic application at 2-5%, systemic absorption is minimal. Multiple clinical trials of topical TXA report no systemic adverse events. The antifibrinolytic risk is dose- and route-dependent and is not transferable from surgical oral dosing to topical cosmetic use. Consumers should not conflate the two. Oral dermatological use requires physician screening; topical cosmetic use does not carry a clotting contraindication for otherwise healthy individuals. 1819315
How long does tranexamic acid take to work?
Most clinical trials measure outcomes at 4 and 8 weeks. In the 3% TXA vs hydroquinone split-face RCT (PMID:38918942), significant MASI reductions were observed at both 4 and 8 weeks. In the cetyl tranexamate mesylate 2% open-label study, 79.3% of participants subjectively noticed improved skin tone within 2 weeks. For oral tranexamic acid in melasma, the 2018 review (PMID:29677015) reported that most patients in retrospective studies improved within 2 months at 500 mg/day. Maintenance therapy is typically required as melasma is a chronic condition with high relapse rates on discontinuation. 15203
Can tranexamic acid be combined with other brightening ingredients?
Yes, and combination is well-supported by clinical evidence. A 2025 RCT (n=99) demonstrated TXA 5% combined with niacinamide 4% was equivalent to hydroquinone 4% with a better safety and relapse profile (PMID:41315336); a niosomal formulation of TXA 2% + niacinamide 2% achieved the same result at lower concentrations. Multiple melasma treatment protocols use TXA alongside triple-combination cream (hydroquinone/retinoid/corticosteroid) or with microneedling for enhanced delivery. A review of topical melasma treatments identifies TXA as compatible with ascorbic acid, azelaic acid, and kojic acid as complementary agents addressing different steps of the melanogenesis pathway (PMID:35642229). No published data shows incompatibility with standard brightening co-ingredients. 1798

→ / Related

More from the verified record

12 / References

Sources

23 references · verified 2026-06-13
  1. 1

    Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation

    Maeda K, Naganuma M · Journal of Photochemistry and Photobiology B 47(2-3):136-41 · 1998

  2. 2

    Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review

    Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS · Acta Dermato-Venereologica 97(7):776-781 · 2017

  3. 3

    Oral Tranexamic Acid for the Treatment of Melasma: A Review

    Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M · Dermatologic Surgery 44(6):814-825 · 2018

  4. 4

    Melasma Treatment: An Evidence-Based Review

    McKesey J, Tovar-Garza A, Pandya AG · American Journal of Clinical Dermatology 21(2):173-225 · 2020

  5. 5

    Tranexamic Acid Inhibits Angiogenesis and Melanogenesis in Vitro by Targeting VEGF Receptors

    Zhu JW, Ni YJ, Tong XY, Guo X, Wu XP, Lu ZF · International Journal of Medical Sciences 17(7):903-911 · 2020

  6. 6

    Whitening effects of cosmetic formulation in the vascular component of skin pigmentation

    Pereira AFC, Igarashi MH, Mercuri M, Pereira AF, Pinheiro ALTA, Silva MS, Facchini G, Eberlin S · Journal of Cosmetic Dermatology 19(1):154-160 · 2020

  7. 7

    Melasma treatment: a systematic review

    Neagu N, Conforti C, Agozzino M, Marangi GF, Morariu SH, Pellacani G, Persichetti P, Piccolo D, Segreto F, Zalaudek I, Dianzani C · Journal of Dermatological Treatment 33(4):1816-1837 · 2022

  8. 8

    Histological changes in facial melasma after treatment with triple combination cream with or without oral tranexamic acid and/or microneedling: A randomised clinical trial

    Cassiano DP, Espósito ACC, Hassun KM, de Andrade Lima MMD, de Andrade Lima EV, Miot LDB, Miot HA, Bagatin E · Indian Journal of Dermatology, Venereology and Leprology 88(6):761-770 · 2022

  9. 9

    Topical Treatments for Melasma and Their Mechanism of Action

    González-Molina V, Martí-Pineda A, González N · Journal of Clinical and Aesthetic Dermatology 15(5):19-28 · 2022

  10. 10

    Tranexamic acid in melasma: A focused review on drug administration routes

    Konisky H, Balazic E, Jaller JA, Khanna U, Kobets K · Journal of Cosmetic Dermatology 22(4):1197-1206 · 2023

  11. 11

    Optimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus

    Desai S, Chan L, Handog E, Djojoseputro L, Lim J, Ling R, Nguyen H, Tam E, Tang J, Thng S, Tran H · Journal of Drugs in Dermatology 22(4):386-392 · 2023

  12. 12

    The efficacy and safety of microneedling with topical tranexamic acid for melasma treatment: A systematic review and meta-analysis

    Feng X, Su H, Xie J · Journal of Cosmetic Dermatology 23(1):33-43 · 2024

  13. 13

    The Use of Tranexamic Acid in Dermatology

    Gaćina K, Krstanović Ćosić A · Acta Clinica Croatica 62(2):368-372 · 2023

  14. 14

    Tranexamic Acid Ameliorates Skin Hyperpigmentation by Downregulating Endothelin-1 Expression in Dermal Microvascular Endothelial Cells

    Liu LX, Liao ZK, Dong BQ, Jiang S, Lei TC · Annals of Dermatology 36(3):151-162 · 2024

  15. 15

    The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial

    Yasnova N, Sirait SP, Rahmayunita G · Acta Dermatovenerologica Alpina Pannonica et Adriatica 33(2):83-88 · 2024

  16. 16

    Tranexamic Acid for the Treatment of Hyperpigmentation and Telangiectatic Disorders Other Than Melasma: An Update

    Chen T, Xue J, Wang Q · Clinical and Cosmetic Investigational Dermatology 17:2151-2163 · 2024

  17. 17

    Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial

    Ghasemiyeh P, Fazelzadeh Haghighi N, Dastgheib L, Ranjbar S, Mohammadi-Samani S · Scientific Reports 15(1):42739 · 2025

  18. 18

    Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis

    Lee HC, Thng TGS, Goh CL · Journal of the American Academy of Dermatology 75(2):385-92 · 2016

  19. 19

    Oral tranexamic acid use for melasma is not associated with thromboembolism: Findings from a multicenter propensity score-matched electronic health record cohort

    Hernandez T, Penny K, Culotta N · JAAD International 24:64-66 · 2025

  20. 20

    New topical tranexamic acid derivative for the improvement of hyperpigmentation and inflammation in the sun-damaged skin

    da Silva Souza ID, Lampe L, Winn D · Journal of Cosmetic Dermatology 20(2):561-565 · 2021

  21. 21

    Stability of Tranexamic Acid Mouth Rinse

    Donnelly RF · International Journal of Pharmaceutical Compounding 22(6):469-474 · 2018

  22. 22

    Development of novel topical tranexamic acid liposome formulations

    Manosroi A, Podjanasoonthon K, Manosroi J · International Journal of Pharmaceutics 235(1-2):61-70 · 2002

  23. 23

    Biodegradable derivatives of tranexamic acid as transdermal permeation enhancers

    Vávrová K, Hrabálek A, Dolezal P, Holas T, Klimentová J · Journal of Controlled Release 104(1):41-49 · 2005